Document:

EX-10.10

 Exhibit 10.10 

***Text Omitted and Filed Separately 

Confidential Treatment Requested 

Under 17 C.F.R. §§ 200.80(b)(4) and 230.406 
  

 PUBLIC HEALTH SERVICE 

PATENT LICENSE AGREEMENT — EXCLUSIVE 

COVER PAGE 
 For PHS internal use only:

 License Number: L-110-2012/0 

License Application Number: A-241-2009 

Serial Number(s) of Licensed Patent(s) or Patent Application(s): 

U.S. Patent No. [***] (HHS Ref. No. [***]) 

U.S. Patent Application No. [***] (HHS Ref. No. [***]) 

PCT Application No. [***] (HHS Ref. No. [***]) 

Licensee: ERYTECH Pharma 

Public Benefit(s): Development of a diagnostic test designed to identify patients more likely to benefit from treatment with certain cancer
therapeutics, and, as a result, potentially increase effectiveness of the cancer treatment. Being able to more closely identify patients who will benefit from a treatment may also reduce overall healthcare costs by screening out those patients who
will not benefit from the treatment. 
 This Patent License Agreement, hereinafter referred to as the “Agreement”, consists of this Cover
Page, an attached Agreement, a Signature Page, Appendix A (List of Patent(s) or Patent Application(s)), Appendix B (Fields of Use and Territory), Appendix C (Royalties), Appendix D (Benchmarks and Performance), Appendix E (Commercial
Development Plan), Appendix F (Example Royalty Report), and Appendix G (Royalty Payment Options). The Parties to this Agreement are: 
  

	 	1)	The National Institutes of Health (“NIH”) or the Food and Drug Administration (“FDA”), as indicated on the Signature Page, hereinafter singly or collectively referred to as
“PHS”, agencies of the United States Public Health Service within the Department of Health and Human Services (“HHS”); and 

  

	 	2)	The person, corporation, or institution identified above or on the Signature Page, having offices at the address indicated on the Signature Page, hereinafter referred to as “Licensee”.

 PHS PATENT LICENSE AGREEMENT – EXCLUSIVE 

PHS and Licensee agree as follows: 
  

	1.	BACKGROUND 

  

	 	1.1	In the course of conducting biomedical and behavioral research, PHS investigators made inventions that may have commercial applicability. 

  
 CONFIDENTIAL TREATMENT
HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. 

 ***Text Omitted and Filed Separately 

Confidential Treatment Requested 

Under 17 C.F.R. §§ 200.80(b)(4) and 230.406 
  

	 	1.2	By assignment of rights from PHS employees and other inventors, HHS, on behalf of the Government, owns intellectual property rights claimed in any United States or foreign patent applications or
patents corresponding to the assigned inventions. HHS also owns any tangible embodiments of these inventions actually reduced to practice by PHS. 

  

	 	1.3	The Secretary of HHS has delegated to PHS the authority to enter into this Agreement for the licensing of rights to these inventions. 

 

	 	1.4	PHS desires to transfer these inventions to the private sector through commercialization licenses to facilitate the commercial development of products and processes for public use and benefit. 

 

	 	1.5	Licensee desires to acquire commercialization rights to certain of these inventions in order to develop processes, methods, or marketable products for public use and benefit. 

 

	2.	DEFINITIONS 

  

	 	2.1	“Affiliate(s)” means a corporation or other business entity, which directly or indirectly is controlled by or controls, or is under common control with Licensee. For this purpose, the term
“control” shall mean ownership of more than fifty percent (50%) of the voting stock or other ownership interest of the corporation or other business entity, or the power to elect or appoint more than fifty percent (50%) of the
members of the governing body of the corporation or other business entity. 

  

	 	2.2	“Benchmarks” mean the performance milestones that are set forth in Appendix D, as amended from time to time in accordance with Paragraph 9.2. 

 

	 	2.3	“Combination Product” means any product that consists of Licensed Products or Licensed Processes and another diagnostic test or companion therapeutic product or any combination of
Licensed Products sold together with another diagnostic test or companion therapeutic product for a single invoiced price. 

  

	 	2.4	“Commercial Development Plan” means the written commercialization plan attached as Appendix E, as amended from time to time in accordance with Paragraph 9.2. 

 

	 	2.5	“First Commercial Sale” means the initial transfer by or on behalf of Licensee or its sublicensees of Licensed Products or the initial practice of a Licensed Process by or on behalf
of Licensee or its sublicensees in exchange for cash or some equivalent to which value can be assigned for the purpose of determining Net Sales, but shall not include a transfer of Licensed Product or practice of Licensed
Process in connection with a clinical trial or for compassionate or named patient use or as part of a sampling or test marketing program. 

  

	 	2.6	“Government” means the Government of the United States of America. 

  

	 	2.7	“Licensed Fields of Use” means the fields of use identified in Appendix B, as amended from time to time in accordance with Paragraph 14.4. 

 

	 	2.8	“Licensed Patent Rights” shall mean: 

  

	 	(a)	Patent applications (including provisional patent applications and PCT patent applications) or patents listed in Appendix A, all divisions and continuations of these applications, all patents issuing from these
applications, divisions, and continuations, and any reissues, reexaminations, and extensions of these patents; 

  
 CONFIDENTIAL TREATMENT
HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. 

 ***Text Omitted and Filed Separately 

Confidential Treatment Requested 

Under 17 C.F.R. §§ 200.80(b)(4) and 230.406 
  

	 	(b)	to the extent that the following contain one or more claims directed to the invention or inventions disclosed in 2.8(a): 

  

	 	(i)	continuations-in-part of 2.8(a); 

  

	 	(ii)	all divisions and continuations of these continuations-in-part; 

  

	 	(iii)	all patents issuing from these continuations-in-part, divisions, and continuations; 

  

	 	(iv)	priority patent application(s) of 2.8(a); and 

  

	 	(v)	any reissues, reexaminations, and extensions of these patents; 

  

	 	(c)	to the extent that the following contain one or more claims directed to the invention or inventions disclosed in 2.8(a): all counterpart foreign and U.S. patent applications and patents to 2.8(a) and 2.8(b), including
those listed in Appendix A; and 

  

	 	(d)	Licensed Patent Rights shall not include 2.8(b) or 2.8 (c) to the extent that they only contain claims directed to new matter which is not the subject matter disclosed in 2.8(a). 

 

	 	2.9	“Licensed Processes” means processes which, in the course of being practiced, would be within the scope of one or more issued or pending claims of the Licensed Patent Rights that have not been
held unpatentable, invalid or unenforceable by an unappealed or unappealable judgment of a court of competent jurisdiction. 

  

	 	2.10	“Licensed Products” means tangible materials which, in the course of manufacture, use, sale, or importation, would be within the scope of one or more issued or pending claims of the Licensed Patent
Rights that have not been held unpatentable, invalid or unenforceable by an unappealed or unappealable judgment of a court of competent jurisdiction. 

  

	 	2.11	“Licensed Territory” means the geographical area identified in Appendix B. 

  

	 	2.12	“Net Sales” means the total gross receipts for sales of Licensed Products or practice of Licensed Processes sold in the Licensed Territory, manufactured in the Licensed
Territory and sold outside the Licensed Territory, and/or manufactured outside of the Licensed Territory and sold in the Licensed Territory by or on behalf of Licensee or its sublicensees, and from leasing, renting,
or otherwise making Licensed Products available in the Licensed Territory to others without sale or other dispositions, whether invoiced or not, less 1) [***]; 2) [***]; 3) [***]; 4) [***]; and, 5) [***]. No deductions shall be made
for [***], or [***]. The term “Net Sales” shall not include any amount for the disposition of Licensed Product or practice of Licensed Process in connection with [***]. 

The [***] among [***] or [***] or [***] for [***] shall not be included in Net Sales. The [***] of Licensed Products or [***]
and [***] by or on behalf of [***], and from [***], shall not be included in Net Sales. If Licensee, or any of its sublicensees, or any third party that purchased Licensed Products from Licensee or any of its
sublicensees, [***], this does not [***] and shall be [***]. Licensee and/or any of its sublicensees agree to [***]. 
 In the event
a Licensed Product is sold or transferred or Licensed Process is performed [***], then the Net Sales for any such [***] shall be determined by [***]. In the event that [***], Net Sales for purposes of determining payments
under this Agreement shall be calculated by [***]. 

  
 CONFIDENTIAL TREATMENT
HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. 

 ***Text Omitted and Filed Separately 

Confidential Treatment Requested 

Under 17 C.F.R. §§ 200.80(b)(4) and 230.406 
  

	 	2.13	“Practical Application” means to manufacture in the case of a composition or product, to practice in the case of a process or method, or to operate in the case of a machine or system; and in each case,
under these conditions as to establish that the invention is being utilized and that its benefits are to the extent permitted by law or Government regulations available to the public on reasonable terms. 

 

	 	2.14	“Research License” means a nontransferable, nonexclusive license under the Licensed Patent Rights to make and to use Licensed Products or Licensed Processes as defined by the
Licensed Patent Rights for purposes of research and not for purposes of commercial manufacture or distribution or in lieu of purchase. 

  

	 	2.15	“Subject Invention” means any Invention of either PHS or Licensee, conceived or first actually reduced to practice in the performance of a Cooperative Research and Development Agreement
(“CRADA”) Research Plan. 

  

	3.	GRANT OF RIGHTS 

  

	 	3.1	PHS hereby grants and Licensee accepts, subject to the terms and conditions of this Agreement, an exclusive license under the Licensed Patent Rights in the Licensed Territory, with the
right to grant sublicenses, as set forth in Article 4, to research, develop, make and have made, to use and have used, to sell and have sold, to offer to sell, and to import any Licensed Products in the Licensed Fields of Use and to
practice and have practiced any Licensed Processes in the Licensed Fields of Use. 

  

	 	3.2	This Agreement confers no license or rights by implication, estoppel, or otherwise under any patent applications or patents of PHS other than the Licensed Patent Rights regardless of whether these
patents are dominant or subordinate to the Licensed Patent Rights. 

  

	 	3.3	[***]. 

  

	4.	SUBLICENSING 

  

	 	4.1	Upon written approval, which shall include prior review of any sublicense agreement by PHS and which shall not be unreasonably withheld, Licensee may enter into sublicensing agreements under the
Licensed Patent Rights subject to the terms set forth in this Article 4. PHS shall review the sublicense [***] from the date of receipt by PHS. Otherwise, the approval of PHS shall be considered reached.

  

	 	4.2	Licensee agrees that any sublicenses granted by it shall provide that the obligations to PHS of Paragraphs 5.1-5.4, 8.1, 10.1, 10.2, 12.5, and 13.8-13.10 of this Agreement, as such provisions relate
to sublicensees, shall be binding upon the sublicensee as if it were a party to this Agreement. Licensee further agrees to attach copies of these Paragraphs to all sublicense agreements. 

 

	 	4.3	Any sublicenses granted by Licensee shall provide for the termination of the sublicense, or the conversion to a license directly between the sublicensees and PHS, at the option of the sublicensee, upon
termination of this Agreement under Article 13. This conversion is subject to PHS approval, not to be unreasonably withheld, and contingent upon acceptance by the sublicensee of the remaining provisions of this Agreement.

  

	 	4.4	Licensee agrees to forward to PHS a complete copy of each fully executed sublicense agreement postmarked within thirty (30) days of the execution of the agreement. To the extent permitted by law,
PHS agrees to maintain each sublicense agreement in confidence. 

  
 CONFIDENTIAL TREATMENT
HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. 

 ***Text Omitted and Filed Separately 

Confidential Treatment Requested 

Under 17 C.F.R. §§ 200.80(b)(4) and 230.406 
  

	5.	STATUTORY AND PHS REQUIREMENTS AND RESERVED GOVERNMENT RIGHTS 

  

	 	5.1	(a) PHS reserves on behalf of the Government an irrevocable, nonexclusive, nontransferable, royalty-free license under the Licensed Patent Rights for the practice of all inventions claimed under the
Licensed Patent Rights throughout the world by or on behalf of the Government and on behalf of any foreign government or international organization pursuant to any existing or future treaty or agreement to which the Government
is a signatory. Prior to the First Commercial Sale, Licensee agrees to provide PHS with reasonable quantities of Licensed Products or materials made through the Licensed Processes for PHS research use,
provided that such quantities can be made available from manufacturing runs conducted by Licensee for its own purposes and such supply will not interfere with Licensee’s requirements and do not involve significant unreimbursed
cost to Licensee; and 

 (b) In the event that the Licensed Patent Rights are Subject Inventions made
under a Cooperative Research and Development Agreement (“CRADA”), Licensee grants to the Government, pursuant to 15 U.S.C. §3710a(b)(1)(A), a nonexclusive, nontransferable, irrevocable, paid-up license under the
Licensed Patent Rights to practice Licensed Patent Rights or have Licensed Patent Rights practiced throughout the world by or on behalf of the Government. In the exercise of this license, the Government shall not
publicly disclose trade secrets or commercial or financial information that is privileged or confidential within the meaning of 5 U.S.C. §552(b)(4) or which would be considered as such if it had been obtained from a non-Federal party. Prior to
the First Commercial Sale, Licensee agrees to provide PHS reasonable quantities of Licensed Products or materials made through the Licensed Processes for PHS research use, provided that such quantities can
be made available from manufacturing runs conducted by Licensee for its own purposes and such supply will not interfere with Licensee’s requirements and do not involve significant unreimbursed cost to Licensee. 

 

	 	5.2	[***]. 

  

	 	5.3	Licensee acknowledges that PHS may enter into future CRADAs under the Federal Technology Transfer Act of 1986 that relate to the subject matter of this Agreement. Licensee agrees not
to unreasonably deny requests for a Research License from future collaborators with PHS when acquiring these rights is necessary in order to make a CRADA project feasible. Licensee may request an opportunity to join as a
party to the proposed CRADA. 

  

	 	5.4	(a) In addition to the reserved license of Paragraph 5.1, PHS reserves the right to grant Research Licenses directly or to require Licensee to grant Research Licenses on reasonable terms. The
purpose of these Research Licenses is to encourage basic research, whether conducted at an academic or corporate facility. In order to safeguard the Licensed Patent Rights, however, PHS shall consult with Licensee before
granting to commercial entities a Research License or before granting a Research License to an academic institution for research funded by a commercial entity or before providing to them, in either case, research samples of materials
made through the Licensed Processes; and 

 (b) In exceptional circumstances, and in the event that Licensed Patent
Rights are Subject Inventions made under a CRADA, the Government, pursuant to 15 U.S.C. §3710a(b)(1)(B), retains the right to require the Licensee to grant to a responsible

  
 CONFIDENTIAL TREATMENT
HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. 

 ***Text Omitted and Filed Separately 

Confidential Treatment Requested 

Under 17 C.F.R. §§ 200.80(b)(4) and 230.406 
  

 
applicant a nonexclusive, partially exclusive, or exclusive sublicense under the Licensed Patent Rights to use the Licensed Patent Rights in a Licensed Field of Use on terms that
are reasonable under the circumstances, or if Licensee fails to grant this license, the Government retains the right to grant the license itself. The exercise of these rights by the Government shall only be in exceptional
circumstances and only if the Government determines: 
  

	 	(i)	the action is necessary to meet health or safety needs that are not reasonably satisfied by Licensee; 

  

	 	(ii)	the action is necessary to meet requirements for public use specified by Federal regulations, and these requirements are not reasonably satisfied by the Licensee; or 

 

	 	(iii)	the Licensee has failed to comply with an agreement containing provisions described in 15 U.S.C. §3710a(c)(4)(B); and 

 

	 	(c)	The determination made by the Government under this Paragraph 5.4 is subject to administrative appeal and judicial review under 35 U.S.C. §203(b). 

 

	6.	ROYALTIES AND REIMBURSEMENT 

  

	 	6.1	Licensee agrees to pay PHS [***] as set forth in Appendix C. 

  

	 	6.2	Licensee agrees to pay PHS [***] as set forth in Appendix C. 

  

	 	6.3	Licensee agrees to pay PHS [***] as set forth in Appendix C. 

  

	 	6.4	Licensee agrees to pay PHS [***] as set forth in Appendix C. 

  

	 	6.5	Licensee agrees to pay PHS [***] as set forth in Appendix C. 

  

	 	6.6	PHS acknowledges that Licensee is willing to sell the Licensed Products (as defined in Paragraph 2.10) throughout the world and that this Agreement shall apply to the manufacture, sale, or
importation of Licensed Products only in or into the Licensed Territory, as the Licensed Patent Rights are effective only for the Licensed Territory (as defined in Paragraph 2.12 and Appendix B). Therefore, for the
avoidance of doubt, PHS shall only be entitled to royalties or other considerations from (a) the sale of Licensed Products in the United States by the Licensee or any of its sublicensees, (b) the sale outside the
United States of Licensed Products manufactured in the United States by the Licensee or any of its sublicensees, and/or (c) the importation for any purpose or resale in the United States of Licensed Products originally
manufactured and sold outside of the United States, which does not constitute patent exhaustion for the purposes of this Agreement. 

  

	 	6.7	A patent or patent application licensed under this Agreement shall cease to fall within the Licensed Patent Rights for the purpose of computing earned royalty payments in any given country on the earliest
of the dates that: 

  

	 	(a)	the application has been abandoned and not continued; 

  

	 	(b)	the patent expires or irrevocably lapses, 

  
 CONFIDENTIAL TREATMENT
HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. 

 ***Text Omitted and Filed Separately 

Confidential Treatment Requested 

Under 17 C.F.R. §§ 200.80(b)(4) and 230.406 
  

	 	(c)	the patent has been held to be invalid or unenforceable by an unappealed or unappealable decision of a court of competent jurisdiction or administrative agency; or 

 

	 	(d)	the application has been pending for more than [***] from the earliest claimed priority date. However, should the application issue the patent will fall within the Licensed Patent Rights for the purpose of
computing earned royalty payments. 

  

	 	6.8	No multiple royalties shall be payable because any Licensed Products or Licensed Processes are covered by more than one of the Licensed Patent Rights. For the sake of clarity and not in limitation
of the foregoing, in the event performance of a Licensed Process involves use of a Licensed Product, only one royalty shall be paid. 

  

	 	6.9	On sales of Licensed Products by Licensee [***] made [***], the value of [***] shall be [***], based on [***]. 

  

	 	6.10	With regard to [***], and [***], 

  

	 	(a)	Licensee shall [***]. 

  

	 	(b)	PHS shall [***]. 

  

	 	6.11	With regard to [***], and [***], PHS, [***], may [***], provided that [***]: 

  

	 	(i)	to pay PHS [***]; 

  

	 	(ii)	to pay [***]. However, in this event, [***]; or 

  

	 	(iii)	in limited circumstances, Licensee may [***]. In that event, Licensee shall [***]. 

  

	 	6.12	PHS agrees, upon written request, to [***] with [***]. Licensee agrees that [***] shall be treated as confidential commercial information and shall not be released to a third party except as required by
law or a court of competent jurisdiction other than to Licensee’s attorneys and accountants. 

  

	 	6.13	Licensee may elect to [***] upon [***] and [***]. 

  

	7.	PATENT FILING, PROSECUTION, AND MAINTENANCE 

  

	 	7.1	Except as otherwise provided in this Article 7, PHS agrees to take responsibility for, but to consult with, the Licensee in the preparation, filing, prosecution, and maintenance of any and all patent
applications or patents included in the Licensed Patent Rights and shall furnish copies of relevant patent-related documents to Licensee. PHS shall provide Licensee with at least fourteen (14) days to comment on any
document that PHS intends to file or to cause to be filed with the relevant intellectual property or patent office, unless fourteen (14) days is not available prior to the statutory deadline for any document that PHS intends to
file or caused to be filed with the relevant intellectual property or patent office, in which case PHS shall provide Licensee with as much opportunity as reasonably possible prior to the statutory deadline for Licensee to comment.
PHS shall consider in good faith Licensee’s comments. 

  
 CONFIDENTIAL TREATMENT
HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. 

 ***Text Omitted and Filed Separately 

Confidential Treatment Requested 

Under 17 C.F.R. §§ 200.80(b)(4) and 230.406 
  

	 	7.2	Each party shall promptly inform the other as to all matters that come to its attention that may affect the preparation, filing, prosecution, or maintenance of the Licensed Patent Rights and provide each other
with at least fourteen (14) days to provide comments and suggestions with respect to the preparation, filing, prosecution, and maintenance of Licensed Patent Rights, unless fourteen (14) days is not available prior to the statutory
deadline of a potentially affected document, in which case the Parties will provide each other with as much opportunity as reasonably possible to comment and offer suggestions prior to the statutory deadline. Each party’s comments and
suggestions shall be considered by the other party in good faith. 

  

	8.	RECORD KEEPING 

  

	 	8.1	Licensee agrees to keep accurate and correct records of Licensed Products made, used, sold, or imported and Licensed Processes practiced under this Agreement appropriate to determine the
amount of royalties due PHS. These records shall be retained for at least [***] years following a given reporting period and shall be available during normal business hours for inspection, at the expense of PHS, by an accountant or
other designated auditor selected by PHS for the sole purpose of verifying reports and royalty payments hereunder. The accountant or auditor shall only disclose to PHS information relating to the accuracy of reports and royalty
payments made under this Agreement. If an inspection shows an underreporting or underpayment in excess of [***] for any twelve (12) month period, then Licensee shall reimburse PHS for the cost of the inspection at the time
Licensee pays the unreported royalties, including any additional royalties as required by Paragraph 9.8. All royalty payments required under this Paragraph shall be due within [***] of the date PHS provides Licensee notice of
the payment due. If an inspection shows an over reporting or over payment or an accurate reporting or payment, PHS shall promptly credit to Licensee any overpayment identified as part of an audit towards the earned royalties on Net
Sales due to PHS from the Licensee in future year(s), as the case may be and shall pay for the entire cost of the inspection. 

  

	 	8.2	Licensee agrees to have an audit of sales and royalties conducted by an independent auditor at least every [***] years if royalties payable to PHS on annual sales of the Licensed Products or
Licensed Processes are over [***] dollars. The audit shall address, at a minimum, the amount of gross sales by or on behalf of Licensee during the audit period, terms of the license as to percentage or fixed royalty to be remitted to
the Government, the amount of royalties owed to the Government under this Agreement, and whether the royalties owed have been paid to the Government and is reflected in the records of the Licensee. The audit shall
also indicate the PHS license number, product, and the time period being audited. A report certified by the auditor shall be submitted promptly by the auditor directly to PHS on completion. Licensee shall pay for the entire cost
of the audit. 

  

	 	8.3	To the extent permitted by applicable law, PHS agrees to maintain any information and reports obtained under this Article 8 in confidence in accordance with the confidentiality requirements specified in Paragraph
9.9. 

  

	9.	REPORTS ON PROGRESS, BENCHMARKS, SALES, AND PAYMENTS 

  

	 	9.1	Prior to signing this Agreement, Licensee has provided PHS with the Commercial Development Plan in Appendix E, under which Licensee intends to bring the subject matter of the
Licensed Patent Rights to the point of Practical Application. This Commercial Development Plan is hereby incorporated by reference into this Agreement. Based on this plan, performance Benchmarks are determined as
specified in Appendix D. 

 Licensee shall provide written annual reports on its product development progress or
efforts to commercialize under the Commercial Development Plan for each of the Licensed Fields of Use  

  
 CONFIDENTIAL TREATMENT
HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. 

 ***Text Omitted and Filed Separately 

Confidential Treatment Requested 

Under 17 C.F.R. §§ 200.80(b)(4) and 230.406 
  

 
within [***] after December 31 of each calendar year. These progress reports shall include, but not be limited to: progress on research and development, status of applications for regulatory
approvals, establishment of manufacturing sites for Licensed Product(s), and status of sublicensing, marketing, importing, and sales during the preceding calendar year, as well as, plans for the present calendar year. PHS also
encourages these reports to include information on any of Licensee’s public service activities that relate to the Licensed Patent Rights. If reported progress differs from that projected in the Commercial Development Plan
and Benchmarks, Licensee shall explain the reasons for these differences. In the annual report, Licensee may propose amendments to the Commercial Development Plan, acceptance of which by PHS may not be denied
unreasonably. Licensee agrees to provide any additional information reasonably required by PHS to evaluate Licensee’s performance under this Agreement. Licensee may amend the Benchmarks at any time upon
written approval by PHS. PHS shall not unreasonably withhold approval of any request of Licensee to extend the time periods of the Benchmarks if the request is supported by a reasonable showing by Licensee of
diligence in its performance under the Commercial Development Plan and toward bringing the Licensed Products to the point of Practical Application as defined in 37 CFR §404.3(d). Licensee shall amend the
Commercial Development Plan and Benchmarks at the request of PHS to address any Licensed Fields of Use not specifically addressed in the plan originally submitted. 

 

	 	9.2	If PHS receives [***] for which [***] shall notify Licensee, in writing, of the existence of [***]. Upon receipt of such written notice, Licensee shall either: (a) [***]; or (b) provided
that, [***] and/or has not [***]; or (c) provided that, [***]; or both (b) and (c). If Licensee [***] (a) [***] (b) [***] (c) [***]; or both (b) and (c), PHS shall [***]. 

 

	 	9.3	Licensee shall report to PHS the dates for achieving Benchmarks specified in Appendix D and the First Commercial Sale in each country in the Licensed Territory within [***] of such
occurrences. 

  

	 	9.4	Licensee shall submit to PHS, within [***] after each calendar half-year ending June 30 and December 31 commencing after the earlier of the date of First Commercial Sale or the date of any
other sale or disposition on which a royalty is due under this Agreement, a royalty report, as described in the example in Appendix F, setting forth for the preceding half-year period the amount of the Licensed Products sold in the
Licensed Territory or the amount of the Licensed Products sold outside the Licensed Territory and manufactured in the Licensed Territory or Licensed Processes practiced by or on behalf of Licensee within the
Licensed Territory, the Net Sales, and the amount of royalty accordingly due. With each royalty report, Licensee shall submit payment of earned royalties due. If no earned royalties are due to PHS for any reporting
period, the written report shall so state. The royalty report shall be certified as correct by an authorized officer of Licensee and shall include a detailed listing of all deductions made under Paragraph 2.11 to determine Net Sales
made under Article 6 to determine royalties due. The royalty report shall also identify the site of manufacture for Licensed Product(s) sold in the United States. 

 

	 	9.5	Licensee agrees to forward semi-annually to PHS a copy of these reports received by Licensee from its sublicensees during the preceding half-year period as shall be pertinent to a royalty accounting
to PHS by Licensee for activities under the sublicense. 

  

	 	9.6	Royalties due under Article 6 shall be paid in U.S. dollars and payment options are listed in Appendix G. For conversion of Net Sales in foreign currency to U.S. dollars, the conversion rate shall be the New York
foreign exchange rate quoted in The Wall Street Journal on the last day of the applicable reporting period. Any value-added taxes or other out-of-pocket expenses incurred in the transfer or conversion to U.S. dollars shall be paid entirely by
Licensee. The royalty report required by Paragraph 9.5 shall be mailed to PHS at its address for Agreement Notices indicated on the Signature Page. 

  
 CONFIDENTIAL TREATMENT
HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. 

 ***Text Omitted and Filed Separately 

Confidential Treatment Requested 

Under 17 C.F.R. §§ 200.80(b)(4) and 230.406 
  

	 	9.7	Licensee shall be solely responsible for determining if any tax on royalty income is owed outside the United States and, to the extent permissible by applicable law, shall pay the tax and be responsible for all
filings with appropriate agencies of foreign governments. 

  

	 	9.8	Additional royalties may be assessed by PHS on any payment that is more than [***] overdue at the rate of [***] percent ([***]%) of the overdue amount per month. This [***] percent ([***]%) per month rate may be
applied retroactively from the original due date until the date of receipt by PHS of the overdue payment and additional royalties. The payment of any additional royalties shall not prevent PHS from exercising any other rights it may
have as a consequence of the lateness of any payment. 

  

	 	9.9	All plans and reports required by this Article 9 shall, to the extent permitted by law, be treated by PHS as commercial and financial information obtained from a person and as privileged and confidential, and any
proposed disclosure of these records by the PHS under the Freedom of Information Act (FOIA), 5 U.S.C. §552 shall be subject to the predisclosure notification requirements of 45 CFR §5.65(d). 

 

	10.	PERFORMANCE 

  

	 	10.1	Licensee shall use its reasonable commercial efforts to bring the Licensed Products and Licensed Processes to Practical Application. “Reasonable commercial efforts” for the purposes
of this provision shall include adherence to the Commercial Development Plan and diligence in its performance of the Benchmarks. The efforts of a sublicensee shall be considered the efforts of Licensee. 

 

	 	10.2	Upon the First Commercial Sale, until the expiration or termination of this Agreement, Licensee shall use its reasonable commercial efforts to make Licensed Products and Licensed
Processes reasonably accessible to the United States public. 

  

	 	10.3	Licensee agrees, after its First Commercial Sale in the United States, to make reasonable quantities of Licensed Products or materials produced through the use of Licensed Processes available
to patient assistance programs in the United States in the indication for which approval has been received if, at the time of First Commercial Sale, both parties agree in good faith that a need for a patient assistance program exists.

  

	 	10.4	Licensee agrees, after its First Commercial Sale and as part of its marketing and product promotion, to develop educational materials (e.g., brochures, website, etc.) directed to patients and physicians
detailing the Licensed Products or medical aspects of the regulatory-approved uses of the Licensed Products. 

  

	 	10.5	Licensee agrees, after its First Commercial Sale, to supply, to the Mailing Address for Agreement Notices indicated on the Signature Page, the Office of Technology Transfer, NIH with an inert
sample of the Licensed Products or Licensed Processes or their packaging for educational and display purposes only. 

  

	11.	INFRINGEMENT AND PATENT ENFORCEMENT 

  

	 	11.1	PHS and Licensee agree to notify each other promptly of each infringement or possible infringement of the Licensed Patent Rights, as well as, any facts which may affect the validity, scope, or
enforceability of the Licensed Patent Rights of which either party becomes aware. 

  
 CONFIDENTIAL TREATMENT
HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. 

 ***Text Omitted and Filed Separately 

Confidential Treatment Requested 

Under 17 C.F.R. §§ 200.80(b)(4) and 230.406 
  

	 	11.2	Pursuant to this Agreement and the provisions of Chapter 29 of Title 35, United States Code, Licensee may: 

  

	 	(a)	bring suit in its own name, at its own expense, and on its own behalf for infringement of presumably valid claims in the Licensed Patent Rights; 

 

	 	(b)	in any suit, enjoin infringement and collect for its use, damages, profits, and awards of whatever nature recoverable for the infringement; or 

 

	 	(c)	settle any claim or suit for infringement of the Licensed Patent Rights provided, however, that PHS and appropriate Government authorities shall have the first right to take such actions; and

  

	 	(d)	If Licensee desires to initiate a suit for patent infringement, Licensee shall notify PHS in writing. If PHS does not notify Licensee of its intent to pursue legal action within ninety
(90) days, Licensee shall be free to initiate suit. PHS shall have a continuing right to intervene in the suit. Licensee shall take no action to compel the Government either to initiate or to join in any suit for
patent infringement. Licensee may request the Government to initiate or join in any suit if necessary to avoid dismissal of the suit. Should the Government be made a party to any suit, Licensee shall reimburse the
Government for any costs, expenses, or fees which the Government incurs as a result of the motion or other action, including all costs incurred by the Government in opposing the motion or other action. In all cases,
Licensee agrees to keep PHS reasonably apprised of the status and progress of any litigation. Before Licensee commences an infringement action, Licensee shall notify PHS and give careful consideration to the views
of PHS and to any potential effects of the litigation on the public health in deciding whether to bring suit. 

  

	 	11.3	In the event that a declaratory judgment action alleging invalidity or non-infringement of any of the Licensed Patent Rights shall be brought against Licensee or raised by way of counterclaim or
affirmative defense in an infringement suit brought by Licensee under Paragraph 11.2, pursuant to this Agreement and the provisions of Chapter 29 of Title 35, United States Code or other statutes, Licensee may:

  

	 	(a)	defend the suit in its own name, at its own expense, and on its own behalf for presumably valid claims in the Licensed Patent Rights; 

 

	 	(b)	in any suit, ultimately to enjoin infringement and to collect for its use, damages, profits, and awards of whatever nature recoverable for the infringement; and 

 

	 	(c)	settle any claim or suit for declaratory judgment involving the Licensed Patent Rights provided, however, that PHS and appropriate Government authorities shall have the first right to take these
actions and shall have a continuing right to intervene in the suit; and 

  

	 	(d)	 If PHS does not notify Licensee of its intent to respond to the legal action within a reasonable
time, Licensee shall be free to do so. Licensee shall take no action to compel the Government either to initiate or to join in any declaratory judgment action. Licensee may request the Government to initiate or to
join any suit if necessary to avoid dismissal of the suit. Should the Government be made a party to any suit by motion or any other action of Licensee, Licensee shall reimburse the Government for any costs, expenses, or
fees, which the Government incurs as a result of the motion or other action. If Licensee elects not to defend against the declaratory judgment action, PHS, at its option, may do so at its own expense. In all cases,
Licensee agrees to keep PHS reasonably 

  
 CONFIDENTIAL TREATMENT
HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. 

 ***Text Omitted and Filed Separately 

Confidential Treatment Requested 

Under 17 C.F.R. §§ 200.80(b)(4) and 230.406 
  

	 	
apprised of the status and progress of any litigation. Before Licensee commences an infringement action, Licensee shall notify PHS and give careful consideration to the views
of PHS and to any potential effects of the litigation on the public health in deciding whether to bring suit. 

  

	 	11.4	In any action under Paragraphs 11.2 or 11.3, the expenses including costs, fees, attorney fees, and disbursements, shall be paid by Licensee. The value of any recovery made by Licensee after deduction of
its expenses, in consideration of any sales not made, through court judgment or settlement shall be treated as Net Sales and subject to earned royalties. 

  

	 	11.5	PHS shall cooperate fully with Licensee in connection with any action under Paragraphs 11.2 or 11.3. PHS agrees promptly to provide access to all necessary documents and to render reasonable
assistance in response to a request by Licensee. 

  

	12.	NEGATION OF WARRANTIES AND INDEMNIFICATION 

  

	 	12.1	PHS offers no warranties other than those specified in Article 1. 

  

	 	12.2	PHS does not warrant the validity of the Licensed Patent Rights and makes no representations whatsoever with regard to the scope of the Licensed Patent Rights, or that the Licensed Patent
Rights may be exploited without infringing other patents or other intellectual property rights of third parties. 

  

	 	12.3	PHS MAKES NO WARRANTIES, EXPRESS OR IMPLIED, OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OF ANY SUBJECT MATTER DEFINED BY THE CLAIMS OF THE LICENSED PATENT RIGHTS OR TANGIBLE MATERIALS RELATED
THERETO. 

  

	 	12.4	PHS does not represent that it shall commence legal actions against third parties infringing the Licensed Patent Rights. 

 

	 	12.5	Licensee shall indemnify and hold PHS, its employees, students, fellows, agents, and consultants harmless from and against all liability, demands, damages, expenses, and losses, including but not limited
to death, personal injury, illness, or property damage, asserted in any claim or incurred in the defense of any claim arising in connection with or arising out of: 

 

	 	(a)	the use by or on behalf of Licensee, its sublicensees, directors, employees, or third parties of any Licensed Patent Rights; or 

 

	 	(b)	the design, manufacture, distribution, or use of any Licensed Products, Licensed Processes or materials by Licensee, or other products or processes developed by Licensee in connection with or
arising out of the Licensed Patent Rights. 

  

	 	12.6	Notwithstanding the foregoing, the indemnity obligations of Licensee shall not apply with respect to the gross negligence or willful misconduct of PHS or its agents or employees. 

 

	 	12.7	Licensee agrees to maintain a liability insurance program consistent with sound business practice. 

  
 CONFIDENTIAL TREATMENT
HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. 

 ***Text Omitted and Filed Separately 

Confidential Treatment Requested 

Under 17 C.F.R. §§ 200.80(b)(4) and 230.406 
  

	13.	TERM, TERMINATION, AND MODIFICATION OF RIGHTS 

  

	 	13.1	This Agreement is effective when signed by all parties, unless the provisions of Paragraph 14.15 are not fulfilled, and shall extend to the expiration of the last to expire of the Licensed Patent Rights
unless sooner terminated as provided in this Article 13. [***]. 

  

	 	13.2	In the event that Licensee is in default in the performance of any material obligations under this Agreement, including but not limited to the obligations listed in Paragraph 13.5, and if the default has
not been remedied within [***] after the date of notice in writing of the default, PHS may terminate this Agreement by written notice and pursue outstanding royalties owed through procedures provided by the Federal Debt Collection Act.

  

	 	13.3	In the event that Licensee becomes insolvent, files a petition in bankruptcy, has such a petition filed against it, determines to file a petition in bankruptcy, or receives notice of a third party’s
intention to file an involuntary petition in bankruptcy, Licensee shall immediately notify PHS in writing. 

  

	 	13.4	Licensee shall have a unilateral right to terminate this Agreement or any licenses in any country or territory by giving PHS [***] written notice to that effect. 

 

	 	13.5	PHS shall specifically have the right to terminate, at its option, this Agreement or modify the Agreement, if PHS determines that the Licensee: 

 

	 	(a)	[***]; 

  

	 	(b)	[***]; 

  

	 	(c)	has willfully made a false statement of, or willfully omitted a material fact in the license application or in any report required by this Agreement; 

 

	 	(d)	has committed a material breach of a covenant or agreement contained in this Agreement; 

  

	 	(e)	is not keeping Licensed Products or Licensed Processes reasonably available to the public after commercial use commences; 

 

	 	(f)	cannot reasonably satisfy unmet health and safety needs; or 

  

	 	(g)	cannot reasonably justify a failure to comply with the domestic production requirement of Paragraph 5.2 unless waived. 

  
 CONFIDENTIAL TREATMENT
HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. 

 ***Text Omitted and Filed Separately 

Confidential Treatment Requested 

Under 17 C.F.R. §§ 200.80(b)(4) and 230.406 
  

	 	13.6	In making the determination referenced in Paragraph 13.5, PHS shall take into account the normal course of such commercial development programs conducted with sound and reasonable business practices and judgment
and the annual reports submitted by Licensee under Paragraph 9.2. Prior to invoking termination or modification of this Agreement under Paragraph 13.5 or 13.8, PHS shall give written notice to Licensee providing
Licensee specific notice of, and a [***] opportunity to respond to, PHS’ concerns as to the items referenced in 13.5(a)-13.5(g) or 13.8 and any modifications to the scope of this Agreement intended to take effect at the end
of such [***] period. If Licensee fails to alleviate PHS’ concerns as to the items referenced in 13.5(a)-13.5(g) or 13.8 or fails to initiate corrective action to PHS’ satisfaction, PHS may terminate this
Agreement or, unless Licensee has terminated this Agreement itself during such [***] period, PHS may modify the scope of this Agreement as set forth in the applicable notice provided under this paragraph, provided
that, in the event of an occurrence of the type described in 13.5(f), PHS shall allow Licensee the opportunity described in Paragraph 13.7 in lieu of PHS exercising any termination rights under this Article 13.

  

	 	13.7	When the public health and safety so require, and after written notice to Licensee providing Licensee a [***] opportunity to respond, PHS shall have the right to require Licensee to grant
sublicenses to responsible applicants, on reasonable terms, in the Licensed Field of Use in which such public health or safety issue has arisen, under the Licensed Patent Rights, unless Licensee can reasonably demonstrate that
the granting of the sublicense would not materially increase the availability to the public of the subject matter of the Licensed Patent Rights. PHS shall not require the granting of a sublicense unless the responsible applicant has
first negotiated in good faith with Licensee. 

  

	 	13.8	PHS reserves the right according to 35 U.S.C. §209(d)(3) to terminate or modify the scope of this Agreement if it is determined that this action is necessary to meet the requirements for public use
specified by federal regulations issued after the date of the license and these requirements are not reasonably satisfied by Licensee. 

  

	 	13.9	Within [***] of receipt of written notice of PHS’ unilateral decision to modify or terminate this Agreement to the extent permitted under this Article 13, Licensee may, consistent with the
provisions of 37 CFR §404.11, appeal the decision by written submission to the designated PHS official. The decision of the designated PHS official shall be the final agency decision. Licensee may thereafter exercise any
and all administrative or judicial remedies that may be available. 

  

	 	13.10	Within [***] of expiration or termination of this Agreement under this Article 13, a final report shall be submitted by Licensee. Any royalty payments, including those incurred but not yet paid (such as
any minimum annual royalty due but not yet paid), and those related to patent expense, due to PHS shall become immediately due and payable upon termination or expiration. If terminated under this Article 13, sublicensees may elect to convert
their sublicenses to direct licenses with PHS pursuant to Paragraph 4.3. 

  

	14.	GENERAL PROVISIONS 

  

	 	14.1	Neither party may waive or release any of its rights or interests in this Agreement except in writing. The failure of the Government to assert a right hereunder or to insist upon compliance with any term
or condition of this Agreement shall not constitute a waiver of that right by the Government or excuse a similar subsequent failure to perform any of these terms or conditions by Licensee. 

 

	 	14.2	This Agreement constitutes the entire agreement between the parties relating to the subject matter of the Licensed Patent Rights, Licensed Products and Licensed Processes, and all prior
negotiations, representations, agreements, and understandings are merged into, extinguished by, and completely expressed by this Agreement. 

  
 CONFIDENTIAL TREATMENT
HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. 

 ***Text Omitted and Filed Separately 

Confidential Treatment Requested 

Under 17 C.F.R. §§ 200.80(b)(4) and 230.406 
  

	 	14.3	The provisions of this Agreement are severable, and in the event that any provision of this Agreement shall be determined to be invalid or unenforceable under any controlling body of law, this
determination shall not in any way affect the validity or enforceability of the remaining provisions of this Agreement. 

  

	 	14.4	If either party desires a modification to this Agreement, the parties shall, upon reasonable notice of the proposed modification by the party desiring the change, confer in good faith to determine the
desirability of the modification. No modification shall be effective until a written amendment is signed by authorized representatives of both parties. Written amendment(s) to this Agreement may subject the Licensee to an additional
amendment royalty to be negotiated by the Parties in good faith. Notwithstanding the above mentioned, Licensee may request to replace a Licensed Field of Use from Appendix B, with another field of use by requesting an amendment to the
Agreement. PHS shall not withhold approval of this amendment or subject it to any other amendment of the Agreement provided that : 

  

	 	(a)	Licensee shall pay to PHS an amendment royalty, which shall not exceed [***] dollars ($[***]); and 

  

	 	(b)	PHS has not licensed the field of use requested by Licensee to a third party, at the date of the request. 

  

	 	14.5	The construction, validity, performance, and effect of this Agreement shall be governed by Federal law as applied by the Federal courts in the District of Columbia. 

 

	 	14.6	All Agreement notices required or permitted by this Agreement shall be given by prepaid, first class, registered or certified mail or by an express/overnight delivery service provided by a commercial
carrier, properly addressed to the other party at the address designated on the following Signature Page, or to another address as may be designated in writing by the other party. Agreement notices shall be considered timely if the notices
are received on or before the established deadline date or sent on or before the deadline date as verifiable by U.S. Postal Service postmark or dated receipt from a commercial carrier. Parties should request a legibly dated U.S. Postal Service
postmark or obtain a dated receipt from a commercial carrier or the U.S. Postal Service. Private metered postmarks shall not be acceptable as proof of timely mailing. 

 

	 	14.7	This Agreement shall not be assigned or otherwise transferred (including any transfer by legal process or by operation of law, and any transfer in bankruptcy or insolvency, or in any other compulsory procedure or
order of court) except to Licensee’s Affiliate(s), without the prior written consent of PHS, which such consent shall not be unreasonably withheld, conditioned or delayed. PHS consent or non-consent will be communicated to
the Licensee within fifteen (15) business days. The parties agree that the identity of the parties is material to the formation of this Agreement and that the obligations under this Agreement are nondelegable. In the event
that PHS approves a proposed assignment, Licensee shall pay PHS, as an additional royalty, [***] percent ([***]%) of the fair market value of any consideration received for any assignment of this Agreement which amount,
in the case where an assignment of this Agreement accompanies the sale or assignment of other assets and agreements of Licensee, shall be determined by Licensee in good faith. The foregoing amount shall be paid within [***] of
the assignment. 

  

	 	14.8	 Licensee agrees in its use of any Licensed Product(s) and/or Licensed Process(es) to comply
with all applicable statutes, regulations, and guidelines, including PHS and HHS regulations and guidelines. Licensee agrees not to use any Licensed Product(s) and/or Licensed Process(es) for

  
 CONFIDENTIAL TREATMENT
HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. 

 ***Text Omitted and Filed Separately 

Confidential Treatment Requested 

Under 17 C.F.R. §§ 200.80(b)(4) and 230.406 
  

	 	
research involving human subjects or clinical trials in the United States without complying with 21 CFR Part 50 and 45 CFR Part 46. Licensee agrees not to use any Licensed
Product(s) and/or Licensed Process(es) for research involving human subjects or clinical trials outside of the United States without notifying PHS, in writing, of the research or trials and complying with the applicable regulations
of the appropriate national control authorities. Written notification to PHS of research involving human subjects or clinical trials outside of the United States shall be given no later than [***] prior to commencement of the research or
trials. 

  

	 	14.9	Licensee acknowledges that it is subject to and agrees to abide by the United States laws and regulations (including the Export Administration Act of 1979 and Arms Export Control Act) controlling the export of
technical data, computer software, laboratory prototypes, biological material, and other commodities. The transfer of these items may require a license from the appropriate agency of the U.S. Government or written assurances by
Licensee that it shall not export these items to certain foreign countries without prior approval of this agency. PHS neither represents that a license is or is not required or that, if required, it shall be issued. 

 

	 	14.10	Licensee agrees to mark the Licensed Products or their packaging sold in the United States with all applicable U.S. patent numbers and similarly to indicate “Patent Pending” status. All
Licensed Products manufactured in, shipped to, or sold in other countries shall be marked as legally required in a manner to preserve PHS patent rights in those countries. 

 

	 	14.11	By entering into this Agreement, PHS does not directly or indirectly endorse any product or service provided, or to be provided, by Licensee whether directly or indirectly related to this
Agreement. Licensee shall not state or imply that this Agreement is an endorsement by the Government, PHS, any other Government organizational unit, or any Government employee. Additionally,
Licensee shall not use the names of NIH, FDA, PHS, or HHS or the Government or their employees in any advertising, promotional, or sales literature without the prior written approval of PHS.

  

	 	14.12	The parties agree to attempt to settle amicably any controversy or claim arising under this Agreement or a breach of this Agreement, except for appeals of modifications or termination decisions provided
for in Article 13. Licensee agrees first to appeal any unsettled claims or controversies to the designated PHS official, or designee, whose decision shall be considered the final agency decision. Thereafter, Licensee may
exercise any administrative or judicial remedies that may be available. 

  

	 	14.13	Nothing relating to the grant of a license, nor the grant itself, shall be construed to confer upon any person any immunity from or defenses under the antitrust laws or from a charge of patent misuse, and the
acquisition and use of rights pursuant to 37 CFR Part 404 shall not be immunized from the operation of state or Federal law by reason of the source of the grant. 

  

	 	14.14	Any formal recordation of this Agreement required by the laws of any Licensed Territory as a prerequisite to enforceability of the Agreement in the courts of any foreign jurisdiction or for other
reasons shall be carried out by Licensee at its expense, and appropriately verified proof of recordation shall be promptly furnished to PHS. 

  

	 	14.15	Paragraphs 4.3, 4.4 (but solely with respect to the confidentiality obligations), 8.1, 8.3, 9.5-9.7 (but solely with respect to the final royalty report), 12.1-12.5, 13.9, 13.10, 14.12 and 14.15 of this Agreement
shall survive termination of this Agreement. 

  

	 	14.16	 The terms and conditions of this Agreement shall, at PHS’ sole option, be considered by
PHS to be withdrawn from Licensee’s consideration and the terms and conditions of this Agreement, and the Agreement itself to be null and void, unless this Agreement is executed by the Licensee and a

  
 CONFIDENTIAL TREATMENT
HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. 

 ***Text Omitted and Filed Separately 

Confidential Treatment Requested 

Under 17 C.F.R. §§ 200.80(b)(4) and 230.406 
  

	 	
fully executed original is received by PHS within sixty (60) days from the date of PHS signature found at the Signature Page. 

SIGNATURES BEGIN ON NEXT PAGE 

  
 CONFIDENTIAL TREATMENT
HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. 

 ***Text Omitted and Filed Separately 

Confidential Treatment Requested 

Under 17 C.F.R. §§ 200.80(b)(4) and 230.406 
  

 PHS PATENT LICENSE AGREEMENT — EXCLUSIVE 

SIGNATURE PAGE 
  

							
	For PHS:	 		 		 	
				
	 /s/ Richard U. Rodriguez
	 		 		 	 6-19-12

	Richard U. Rodriguez	 		 		 	Date
	Director, Division of Technology Development and Transfer	 		 		 	
	Office of Technology Transfer	 		 		 	
	National Institutes of Health	 		 		 	
				
	Mailing Address for Agreement notices:	 		 		 	
				
	Chief, Monitoring & Enforcement Branch, DTDT	 		 		 	
	Office of Technology Transfer	 		 		 	
	National Institutes of Health	 		 		 	
	6011 Executive Boulevard, Suite 325	 		 		 	
	Rockville, Maryland 20852-3804 U.S.A.	 		 		 	
	
	For Licensee (Upon, information and belief, the undersigned expressly certifies or affirms that the contents of any statements of Licensee made or referred to in this document are truthful and
accurate.):
				
	by: ERYTECH Pharma.	 		 		 	
				
	 /s/ Pierre-Olivier Goineau
	 		 		 	 8-14-2012

	Signature of Authorized Official	 		 		 	Date
				
	Pierre-Olivier Goineau	 		 		 	
	Chief Executive Officer	 		 		 	
	
	Official and Mailing Address for Agreement notices and for Financial notices (Licensee’s contact person for royalty payments):
				
	Pierre-Oliver Goineau	 		 		 	
	Chief Executive Officer	 		 		 	
				
	Bâtiment Adénine,	 		 		 	
	60 Avenue Rockefeller	 		 		 	
	69008 Lyon, France	 		 		 	
				
	Email Address: [***]	 		 		 	
	Phone: [***]	 		 		 	
	Fax:      [***]	 		 		 	

  
 CONFIDENTIAL TREATMENT
HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. 

 ***Text Omitted and Filed Separately 

Confidential Treatment Requested 

Under 17 C.F.R. §§ 200.80(b)(4) and 230.406 
  

 Any false or misleading statements made, presented, or submitted to the Government, including any
relevant omissions, under this Agreement and during the course of negotiation of this Agreement are subject to all applicable civil and criminal statutes including Federal statutes 31 U.S.C. §§3801-3812 (civil liability) and
18 U.S.C. §1001 (criminal liability including fine(s) or imprisonment). 
 APPENDIX A — PATENT(S) OR PATENT APPLICATION(S)

 Patent(s) or Patent Application(s): 
  

	I.	U.S. Patent No. [***] entitled “[***]” and issued on [***] (HHS Ref No. [***]) 

  

	II.	U.S. Patent Application No. [***] entitled “[***]” and filed on [***] (HHS Ref. No. [***]) 

  

	III.	PCT Application No. [***] entitled “[***]” and filed on [***] (HHS Ref. No. [***]) 

  
 CONFIDENTIAL TREATMENT
HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. 

 ***Text Omitted and Filed Separately 

Confidential Treatment Requested 

Under 17 C.F.R. §§ 200.80(b)(4) and 230.406 
  

 APPENDIX B — LICENSED FIELDS OF USE AND TERRITORY 

 

	I.	Licensed Fields of Use: 

  

	 	(a)	The use of the Licensed Patent Rights limited to an FDA-approved companion diagnostic test predictive of L-asparaginase therapeutic effect in the treatment of [***]. 

 

	 	(b)	The use of the Licensed Patent Rights limited to an FDA-approved companion diagnostic test predictive of L-asparaginase therapeutic effect in the treatment of [***]. 

 

	 	(c)	The use of the Licensed Patent Rights limited to an FDA-approved companion diagnostic test predictive of L-asparaginase therapeutic effect in the treatment of [***]. 

 

	 	(d)	The use of the Licensed Patent Rights limited to an FDA-approved companion diagnostic test predictive of L-asparaginase therapeutic effect in the treatment of [***]. 

 

	 	(e)	The use of the Licensed Patent Rights limited to an FDA-approved companion diagnostic test predictive of L-asparaginase therapeutic effect in the treatment of [***]. 

 

	 	(f)	The use of the Licensed Patent Rights limited to an FDA-approved companion diagnostic test predictive of L-asparaginase therapeutic effect in the treatment of [***]. 

 

	 	(g)	The use of the Licensed Patent Rights limited to an FDA-approved companion diagnostic test predictive of L-asparaginase therapeutic effect in the treatment of [***]. 

 

	 	(h)	The use of the Licensed Patent Rights limited to an FDA-approved companion diagnostic test predictive of L-asparaginase therapeutic effect in the treatment of [***]. 

[***]. 
  

	II.	Licensed Territory: 

  

	 	(a)	United States 

  
 CONFIDENTIAL TREATMENT
HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. 

 ***Text Omitted and Filed Separately 

Confidential Treatment Requested 

Under 17 C.F.R. §§ 200.80(b)(4) and 230.406 
  

 APPENDIX C — ROYALTIES 

Royalties: 
  

	I.	Licensee agrees to pay to PHS a [***] license issue royalty in the amount of thirty thousand dollars ($30,000.00) within sixty (60) days from the effective date of this Agreement.

  

	II	Licensee agrees to pay to PHS a [***] royalty in the amount of [***] dollars ($[***]) due and payable on [***], and may be [***]: 

 

	III.	(a)    Licensee agrees to pay PHS [***] royalties of [***] up to [***] dollars ($[***]) by or on behalf of Licensee [***]. 

 

	 	(b)	Licensee agrees to pay PHS [***] royalties of [***] of over [***] dollars ($[***]) by or on behalf of Licensee [***]. 

 

	 	(i)	In any given calendar year where the [***] exceeds [***] dollars ($[***]), by or on behalf of the Licensee [***], Licensee agrees to pay PHS [***] royalties of [***] percent ([***]%) on [***].

  

	 	(ii)	In the subsequent calendar year(s), the [***] royalty rate [***] by or on behalf of the Licensee [***] will [***] until such time as the [***]. 

 

	 	(c)	If Licensee [***] finds it necessary or desirable to [***] of [***] to [***] or to [***], Licensee may [***]. However, in no event shall [***] be [***]. 

 

	IV.	Licensee agrees to pay [***] royalties within [***] of achieving each [***]: 

  

	 	(a)	[***] dollars ($[***]) upon [***]. 

  

	 	(b)	[***] ($[***]) upon [***]. 

 The aforementioned [***] are payable [***] except that
Licensee shall also pay [***] of the aforementioned [***] upon the [***] but solely [***]. 
  

	V.	Licensee agrees to pay PHS additional sublicensing royalties of any Sublicense Income, as defined below, received specifically for granting each sublicense of the license granted with respect to
Licensed Patent Rights within [***]: 

  

	 	(a)	For any such sublicense executed by the Licensee [***], Licensee agrees to pay a [***]; and 

  

	 	(b)	For any sublicense executed by the Licensee after [***], but [***], Licensee agrees to pay a [***]; and 

  

	 	(c)	For any sublicense executed by the Licensee after [***], Licensee agrees to pay [***]. 

For purposes of the foregoing, “Sublicense Income” shall mean [***] but will not include: (a) [***], (b) [***];
(c) [***]; (d) [***]; (e) [***] and (f) [***]. 
  

	VI.	The estimated amount of the royalty due under [***] is [***] as of [***]. This is only a good faith estimate and [***]. 

  
 CONFIDENTIAL TREATMENT
HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. 

 ***Text Omitted and Filed Separately 

Confidential Treatment Requested 

Under 17 C.F.R. §§ 200.80(b)(4) and 230.406 
  

 APPENDIX D — BENCHMARKS AND PERFORMANCE 

Licensee agrees to the following Benchmarks for its performance under this Agreement and, within [***] days of achieving a
Benchmark, shall notify PHS that the Benchmark has been achieved 
  

	I.	[***]. 

  

	II.	[***]. 

  

	III.	[***]. 

  

	IV.	[***]. 

  
 CONFIDENTIAL TREATMENT
HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. 

 ***Text Omitted and Filed Separately 

Confidential Treatment Requested 

Under 17 C.F.R. §§ 200.80(b)(4) and 230.406 
  

 APPENDIX E — COMMERCIAL DEVELOPMENT PLAN 

[***] 

  
 CONFIDENTIAL TREATMENT
HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. 

 ***Text Omitted and Filed Separately 

Confidential Treatment Requested 

Under 17 C.F.R. §§ 200.80(b)(4) and 230.406 
  

 APPENDIX F — EXAMPLE ROYALTY REPORT 

Required royalty report information includes: 
  

	•	 	OTT license reference number (L-XXX-200X/0) 

  

	•	 	Reporting period 

  

	•	 	Catalog number and units sold of each Licensed Product (domestic and foreign) 

  

	•	 	Gross Sales per catalog number per country 

  

	•	 	Total Gross Sales 

  

	•	 	Itemized deductions from Gross Sales 

  

	•	 	Total Net Sales 

  

	•	 	Earned Royalty Rate and associated calculations 

  

	•	 	Gross Earned Royalty 

  

	•	 	Adjustments for Minimum Annual Royalty (MAR) and other creditable payments made 

  

	•	 	Net Earned Royalty due 

 Example 

 

									
	 Catalog Number
	 	Product Name	 	Country	 	Units Sold	 	Gross Sales
(US$)
	1	 	A	 	US	 	250	 	[***]
	1	 	A	 	UK	 	32	 	[***]
	1	 	A	 	France	 	25	 	[***]
	2	 	B	 	US	 	0	 	[***]
	3	 	C	 	US	 	57	 	[***]
	4	 	D	 	US	 	12	 	[***]

  

															
		 		 	Total Gross Sales	  	[***]	 	
		 	Less Deductions:	 		  		 	
		 		 		 		 	Freight	 		  	[***]	 	
		 		 		 		 	Returns	 		  	[***]	 	
		 	    Total Net Sales	 		  	[***]	 	
						
		 		 		 	Royalty Rate	  	[***]	 	
		 		 		 	Royalty Due	  	[***]	 	
		 	    Less Creditable Payments	 		  	[***]	 	
		 		 	Net Royalty Due	  	[***]	 	

  
 CONFIDENTIAL TREATMENT
HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. 

 ***Text Omitted and Filed Separately 

Confidential Treatment Requested 

Under 17 C.F.R. §§ 200.80(b)(4) and 230.406 
  

 APPENDIX G —ROYALTY PAYMENT OPTIONS 

NIH/PHS License Agreements 
 *In
order to process payment via Electronic Funds Transfer sender MUST supply the following information: 
 Procedure for Transfer of
Electronic Funds to NIH for Royalty Payments 
 [***] 

NOTE: Only U.S. banks can wire directly to the Federal Reserve Bank. Foreign banks cannot wire directly to the Federal Reserve Bank, but must go through an
intermediary U.S. bank. Foreign banks may send the wire transfer to the U.S. bank of their choice, who, in turn forwards the wire transfer to the Federal Reserve Bank. 

Checks drawn on a U.S. bank account should be sent directly to the following address: 

National Institutes of Health (NIH) 
 P.O. Box 979071 

St. Louis, MO 63197-9000 
 Overnight or courier deliveries
should be sent to the following address: 
 US Bank 

Government Lockbox SL-MO-C2GL 
 1005 Convention Plaza 

St. Louis, MO 63101 
 Phone: 314-418-4087 

Checks drawn on a foreign bank account should be sent directly to the following address: 

National Institutes of Health (NIH) 
 Office of Technology
Transfer 
 Royalties Administration 
 Unit 6011 Executive
Boulevard 
 Suite 325, MSC 7660 
 Rockville, Maryland 20852

 Phone: 301-496-7057 
 All checks should be made
payable to “NIH Patent Licensing”. 
 The OTT Reference Number MUST appear on checks, reports and correspondence 

  
 CONFIDENTIAL TREATMENT
HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. 

 ***Text Omitted and Filed Separately 

Confidential Treatment Requested 

Under 17 C.F.R. §§ 200.80(b)(4) and 230.406 
  

 NATIONAL INSTITUTES OF HEALTH 

FIRST AMENDMENT TO L-110-2012/0 
 This is
the first amendment (“First Amendment”) of the agreement by and between the National Institutes of Health (“NIH”) within the Department of Health and Human Services (“HHS”), and Erytech Pharma
having an effective date of August 14, 2012 and having NIH Reference Number L-110-2012/0 (“Agreement”). This First Amendment, having NIH Reference Number L-110-2012/1, is made between the NIH through the Office of
Technology Transfer, NIH, having an address at 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852-3804, U.S.A., and Erytech Pharma, having an office at Batiment Adenine, 60 Avenue Rockefeller, 69008 Lyon, France (the
“Licensee”). This First Amendment includes, in addition to the amendments made below, 1) a Signature Page, and 2) Attachment 1 (Royalty Payment Information). 

WHEREAS, the NIH and the Licensee desire that the Agreement be amended a first time as set forth below in order to extend the time to
accomplish the clinical benchmarks. 
 NOW, THEREFORE, in consideration of the mutual covenants and promises contained herein, the NIH and the
Licensee, intending to be bound, hereby mutually agree to the following: 
  

	1)	Replace Appendix D of the Agreement with the following: 

  

	 	I.	[***]. 

  

	 	II.	[***]. 

  

	 	III.	[***]. 

  

	 	IV.	[***]. 

  

	2)	Within sixty (60) days of the execution of this First Amendment, the Licensee shall pay the NIH an amendment issue royalty in the sum of [***] US Dollars ($[***]), and payment options may be
found in Attachment 1. 

  

	3)	In the event any provision(s) of the Agreement is/are inconsistent with Attachment 1, such provision(s) is/are hereby amended to the extent required to avoid such inconsistency and to give effect to the shipping
and payment information in such Attachment 1. 

  

	4)	All terms and conditions of the Agreement not herein amended remain binding and in effect. 

  

	5)	The terms and conditions of this First Amendment shall, at the NIH’s sole option, be considered by the NIH to be withdrawn from the Licensee’s consideration and the terms and conditions of
this First Amendment, and the First Amendment itself, to be null and void, unless this First Amendment is executed by the Licensee and a fully executed original is received by the NIH within sixty (60) days from the
date of the NIH’s signature found at the Signature Page. 

  

	6)	This First Amendment is effective upon execution by all parties. 

 SIGNATURES BEGIN ON
NEXT PAGE 

  
 CONFIDENTIAL TREATMENT
HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. 

 ***Text Omitted and Filed Separately 

Confidential Treatment Requested 

Under 17 C.F.R. §§ 200.80(b)(4) and 230.406 
  

 FIRST AMENDMENT TO L-110-2012/0 

SIGNATURE PAGE 
 In Witness Whereof, the
parties have executed this First Amendment on the dates set forth below. Any communication or notice to be given shall be forwarded to the respective addresses listed below. 

 

							
	For the NIH:	 		 		 	
				
	 /s/ Richard U. Rodriguez
	 		 		 	 2-26-14

	Richard U. Rodriguez	 		 		 	Date
	Director, Division of Technology Development and Transfer	 		 		 	
	Office of Technology Transfer	 		 		 	
	National Institutes of Health	 		 		 	
				
	Mailing Address or E-mail Address for Agreement notices and reports:	 		 		 	
				
	Chief, Monitoring & Enforcement Branch, DTDT	 		 		 	
	Office of Technology Transfer	 		 		 	
	National Institutes of Health	 		 		 	
	6011 Executive Boulevard, Suite 325	 		 		 	
	Rockville, Maryland 20852-3804 U.S.A.	 		 		 	
				
	E-mail: LicenseNotices_Reports@mail.nih.gov	 		 		 	

 For the Licensee (Upon information and belief, the undersigned expressly certifies or affirms that the contents of any
statements of the Licensee made or referred to in this document are truthful and accurate.): 
  

							
	 /s/ Pierre-Olivier Goineau
	 		 		 	 3/3/2014

	Signature of Authorized Official	 		 		 	Date
				
	Name: P.O. Goineau	 		 		 	
	Title: COO	 		 		 	

  
 CONFIDENTIAL TREATMENT
HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. 

 ***Text Omitted and Filed Separately 

Confidential Treatment Requested 

Under 17 C.F.R. §§ 200.80(b)(4) and 230.406 
  

	I.	Official and Mailing Address for Agreement notices: 

 Pierre-Olivier Goineau 

CEO 
 Erytech Pharma 

Batiment Adenine 
 60 Avenue
Rockefeller 
 69008 Lyon 

France 
 Phone: [***] 

Email: [***]; contact@ervtech.com 
  

	II.	Official and Mailing Address for Financial notices (the Licensee’s contact person for royalty payments): 

Sebastien Rouchouse 
 Financial
and Administrative Manager 
 Erytech Pharma 

Batiment Adenine 
 60 Avenue
Rockefeller 
 69008 Lyon 

France 
 Phone: [***] 

Email: [***] 
 Any false or misleading statements
made, presented, or submitted to the Government, including any relevant omissions, under this Agreement and during the course of negotiation of this Agreement are subject to all applicable civil and criminal statutes including
Federal statutes 31 U.S.C. §§3801-3812 (civil liability) and 18 U.S.C. §1001 (criminal liability including fine(s) or imprisonment). 

  
 CONFIDENTIAL TREATMENT
HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. 

 ***Text Omitted and Filed Separately 

Confidential Treatment Requested 

Under 17 C.F.R. §§ 200.80(b)(4) and 230.406 
  

 ATTACHMENT 1 – ROYALTY PAYMENT OPTIONS 

The OTT License Number MUST appear on payments, reports and correspondence. 

Automated Clearing House (ACH) for payments through U.S. banks only 

The NIH encourages its licensees to submit electronic funds transfer payments through the Automated Clearing House (ACH). Submit your ACH payment
through the U.S. Treasury web site located at: https://www.pay.gov. Locate the “NIH Agency Form” through the Pay.gov “Agency List”. 

Electronic Funds Wire Transfers 
 The following
account information is provided for wire payments. In order to process payment via Electronic Funds Wire Transfer sender MUST supply the following information within the transmission: 

Drawn on a U.S. bank account via FEDWIRE should be sent directly to the following account: 

[***] 
 Drawn on a foreign
bank account should be sent directly to the following account. Payment must be sent in U.S. Dollars (USD) using the following instructions: 

[***] 

  
 CONFIDENTIAL TREATMENT
HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. 

 ***Text Omitted and Filed Separately 

Confidential Treatment Requested 

Under 17 C.F.R. §§ 200.80(b)(4) and 230.406 
  

 Checks 

All checks should be made payable to “NIH Patent Licensing” 

Checks drawn on a U.S. bank account and sent by US Postal Service should be sent directly to the following address: 

National Institutes of Health (NIH) 

P.O. Box 979071 
 St. Louis, MO
63197-9000 
 Checks drawn on a U.S. bank account and sent by overnight or courier should be sent to the following address:

 US Bank 
 Government Lockbox
SL-MO-C2GL 
 1005 Convention Plaza 

St. Louis, MO 63101 
 Phone:
314-418-4087 
 Checks drawn on a foreign bank account should be sent directly to the following address: 

National Institutes of Health (NIH) 

Office of Technology Transfer 

Royalties Administration Unit 

6011 Executive Boulevard 
 Suite
325, MSC 7660 
 Rockville, Maryland 20852 

  
 CONFIDENTIAL TREATMENT
HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION.EX-10.11

 Exhibit 10.11 

FORM OF OFFER 
 TO
DIRECTORS, OFFICERS OR SPECIFICALLY DESIGNATED PERSONS 
 TO SUBSCRIBE LIABILITY INSURANCE AND PROVIDE INDEMNIFICATION 

WHEREAS: 
 The offering in the United States by ERYTECH Pharma
S.A. (the “Company”) of shares in the form of American Depositary Shares (“ADSs”), one ADS representing one ordinary share of the Company, the filing of forms with the Securities and Exchange
Commission (“SEC”) in connection with such offering and the quotation of the ADSs on the Nasdaq Global Market (“Market”) expose the directors and the officers of the Company to major and specific risks
with respect to their service to the Company. 
 The Company, taking into account the scope of the obligations and possible personal liability of the
directors and officers induced by the U.S. securities laws and the fact that they are significantly more burdensome than under French law, has resolved that the said directors and officers should not be exposed to such personal liability. 

Moreover, in the United States, directors and officers are typically indemnified or insured. As a result, the Company has concluded that in the absence of
such protection against risks sustained by reason of the fact that they are serving as such, individuals might not accept to serve as directors or officers of the Company or might resign from their office. The Company has also concluded that it is
necessary to have such individuals serve on its board of directors and as its officers if it is to achieve its objectives in the international financial and commercial markets. 

It is the Company’s intention to provide said directors and officers with indemnification against liabilities and advancement of expenses in connection
with any matters that arise out of their service to the Company to the fullest extent permitted by applicable laws and regulations. 
 Accordingly,
considering as well the fact that the quotation of the ADSs on the Market is a key factor to the future development of the Company, the Company resolved that providing insurance coverage, indemnification and advancement of expenses to said directors
and officers to the fullest extent permitted by applicable laws and regulations is consistent with the Company’s corporate interest. 
 The undersigned
may also have certain rights to indemnification and/or insurance provided by a private equity fund, venture capital fund, an investment company and certain of their affiliates which have invested in the Company (collectively, the “Fund
Indemnitors”) which the undersigned and the Fund Indemnitors intend to be secondary to the primary obligation of the Company to indemnify undersigned as provided herein, with the Company’s acknowledgement and agreement to the
foregoing being a material condition to undersigned’s willingness to serve as director of the Company to the extent applicable. 
 NOW THEREFORE, THE
COMPANY HEREBY IRREVOCABLY UNDERTAKES AS FOLLOWS: 
  

	1.	Beneficiary 

 The persons, whether individuals or corporations, who may benefit from and accept
the offer (the “Offer”) are: 
  

	 	(a)	a director (a “Director”) of the Company, and 

  

	 	(b)	the Chairman of the Board, the Directeur Général, a Directeur Général Delegué as well as any executive officer, who is not a director, employed by the Company to whom the
Board of Directors of the Company would elect to make the Offer (an “Officer”). 

 A “Beneficiary”,
for the purpose of the Offer, shall be a Director or an Officer having accepted and signed this Offer. 

	2.	Undertaking to Subscribe; Insurance Policy; Indemnification  

 2.1. Upon acceptance and signature
of this Offer by a Beneficiary, subject to approval from the board of directors and the shareholders meeting of the Company in accordance with article L. 225-38 and seq. of the French Commercial Code, the Company shall immediately provide to the
Beneficiary the benefit of one or more director and officer (“D&O”) insurance policies (collectively, the “D&O Insurance Policy”) subscribed with a well-rated insurance company of national or
international repute (the “Insurance Company”) providing D&O insurance coverage in line with best practice for companies in the United States with a similar market capitalization and industry to the Company
(“Best Practices”), to the fullest extent permitted by applicable laws and regulations. Any losses incurred by the Beneficiary for any damages, losses, liabilities, judgments, and amounts paid in settlement (if such
settlement is approved in advance by the Company, which approval shall not be unreasonably withheld), including without limitation all interest, assessments and other charges paid or payable in connection with or in respect of any of the foregoing
(collectively, the “Losses”) if the Beneficiary is or was or becomes a party to or witness or other participant in, or is threatened to be made a party to or witness or other participant in, any threatened, pending or
completed claim, demand, action, suit, proceeding or alternative dispute resolution mechanism, whether civil, administrative, investigative or other, whether formal or informal, or any inquiry or investigation, whether made, instituted or conducted
by the Company or any other party, including without limitation any foreign, federal, state or other governmental entity by reason of (or arising in part out of) any event or occurrence related to the fact that the Beneficiary is or was a Director
or Officer of the Company, or any Subsidiary of the Company (as defined below), or is or was serving at the request of the Company as a director or officer of another corporation, partnership, joint venture, trust or other enterprise, or by reason
of any action or inaction on the part of the Beneficiary while serving in such capacity, shall be referred hereunder, collectively, as an “Indemnifiable Claim”. The Beneficiary shall be compensated for any Indemnifiable Claim
by this D&O Insurance Policy or if not indemnifiable thereunder, by the Company to the fullest extent permitted by law. Also to the fullest extent permitted by applicable laws and regulations, the D&O Insurance Policy shall provide for
indemnification of the Beneficiary in line with Best Practices against reasonable and necessary Expenses (as defined) as a result of the facts, acts or omission described above, in the event the Beneficiary was, is or is threatened to be made, a
party or witness or participant in, by whatever means, a hearing or investigation which the Beneficiary in good faith and reasonably thinks could lead to an action or other relief, suit, proceeding or alternative dispute resolution mechanism,
whether civil, criminal, administrative, or other, whether formal or informal. 
 For purposes of this Offer, a “Subsidiary” shall
mean an entity, which the Company directly or indirectly controls, 50% or more of the entity’s voting securities. 
 For the purpose of the Offer, a
“Claim” means (a) any threatened, asserted, pending or completed claim, demand, action, suit or proceeding, whether civil, criminal, administrative, arbitrative, investigative or other, and whether made pursuant to
foreign federal, state or other law; and (b) any inquiry or investigation, whether made, instituted or conducted by the Company or any other party, including without limitation any foreign, federal, state or other governmental entity, that
Beneficiary determines might lead to the institution of any such claim, demand, action, suit or proceeding. 
 To the fullest extent permitted by applicable
laws and regulations, the D&O Insurance Policy shall provide for indemnification of the Beneficiary in line with Best Practices against reasonable and necessary expenses (including attorneys’ fees and all other costs, expenses and expenses
incurred in connection with investigating, defending, being a witness in or participating in (including on appeal), or preparing to defend, be a witness in or participate in, any such action, suit, proceeding, alternative dispute resolution
mechanism, hearing, inquiry or investigation) (collectively, hereinafter “Expenses”) and any and all Losses in connection with an Indemnifiable Claim. 

The Company shall in the first instance pay on behalf of the Beneficiary any deductible or retention amounts due under the Insurance Policy in connection with
any Indemnifiable Claim or Claim for the payment of Expenses, to the fullest extent permitted by applicable laws and regulations. 
 2.2. As a result of the
acceptance and signature of this Offer by the Beneficiary, a bilateral contract will be formed between the Company and the Beneficiary. 

 2.3. To the fullest extent permitted by applicable laws and regulations, the Company agrees that, so long as a
Director or Officer shall continue to serve as a Director or Officer of the Company or any Subsidiary, or shall continue at the request of the Company to serve as a director or officer of another corporation, partnership, joint venture, trust or
other enterprise, and thereafter so long as a Director or Officer shall be subject to any possible Indemnifiable Claim by reason of the fact that said Director or Officer was a Director or Officer of the Company or any Subsidiary or at the request
of the Company to serve as a director or officer of another corporation, partnership, joint venture, trust or other enterprise, and thereafter, the Company will maintain in effect for the benefit of such Director or Officer one or more valid,
binding and enforceable insurance policies with the Insurance Company providing coverage, including with respect to limits of liability thereunder, at least comparable to that provided in this Offer, and such insurance policy or policies shall be or
be deemed to be the D&O Insurance Policy for all purposes of this Offer. 
  

	3.	Exclusions 

 3.1. The Beneficiary acknowledges that French law allows only the cover of financial
consequences of civil liability in cases of mismanagement and contains material limitations on indemnification or coverage for Losses and/or Expenses and currently prevents the Company, in particular, from indemnifying the Beneficiary for Losses and
Expenses incurred by a Beneficiary that could be deemed a particulary serious breach, with respect to the following Claims: 
  

	 	(a)	any Claim made by the Company or by a shareholder or any other person on behalf of the Company (derivative action); 

  

	 	(b)	any Claim relating to remuneration paid to the Beneficiary, if it shall be determined that such remuneration was not due; 

  

	 	(c)	any Claim for which a judgment is rendered against the Beneficiary for an accounting of profits made from the purchase or sale of, or the procurement to purchase or sell, securities of the Company pursuant to insider
trading laws or regulations; 

  

	 	(d)	any Claim which is based on the Beneficiary’s willful or gross misconduct or on a fraud or a fraudulent misrepresentation, intentional or fraudulent (or deemed to be so) misconduct, whether the Beneficiary has
acted alone or as an accomplice if it should be finally determined that the Beneficiary is guilty of such misconduct; or 

  

	 	(e)	any Claim which is based on the Beneficiary’s criminal actions; 

  

	 	(f)	any fines and penalties of any kind (criminal, public, tax, civil and custom); 

  

	 	(g)	any damage to property of, or personal injury to, any third party including any threat to the environment; 

  

	 	(h)	any Claim which is based on the Beneficiary’s misconduct in its private life; 

  

	 	(g)	any Claim which is based on the consequences of a labor disturbance or the granting of a guarantee. 

 3.2. The
Beneficiary further acknowledges that the D&O Insurance Policy contains or may contain similar limitations on coverage for Losses or Expenses incurred by a Beneficiary, in each case with respect to Indemnifiable Claims, and that it does not
cover Claims: 
  

	 	(a)	pending, if any, at the date this Offer is accepted and signed by the relevant Beneficiary, 

  

	 	(b)	which arise from the settlement of any action or Claim without the Company’s written consent or, 

  

	 	(c)	generally, that cannot be insured under applicable laws and regulations; 

 provided, that the terms of the D&O Insurance Policy shall determine whether insurance coverage is available
to the Beneficiary in connection with any Indemnifiable Claim, and that any limitations, restrictions or exclusions contained in the Insurance Policy that are not mandated by applicable law shall not relieve the Company of its obligation to provide
indemnification to the Beneficiary for Losses and Expenses in each case with respect to Indemnifiable Claims to the fullest extent permitted by applicable laws and regulations. 

 

	4.	Notification and Defense of an Indemnifiable Claim 

 4.1. As soon as practicable after the
written receipt by the Beneficiary of a Indemnifiable Claim, the Beneficiary shall notify the Company in writing thereof, which notification shall specify: 
  

	(a)	the existence and the nature of the Indemnifiable Claim; and 

  

	(b)	the nature and the estimate of the amount of the Losses and Expenses with respect to an Indemnifiable Claim. 

Omission to so notify the Company will not relieve the Company from liability under the Offer, except if thereby the Company has been materially prejudiced.

 4.2. In the event the Company shall be requested by Beneficiary to pay the Expenses or Losses of any Indemnifiable Claim, the Company, if appropriate,
shall be entitled to assume the defense of such Indemnifiable Claim, or to participate to the extent permissible in such Indemnifiable Claim, with counsel reasonably acceptable to Beneficiary. Upon assumption of the defense by the Company and the
retention of such counsel by the Company, the Company shall not be liable to Beneficiary under this Offer for any Expenses of counsel subsequently incurred by Beneficiary with respect to the same Indemnifiable Claim, provided that Beneficiary shall
have the right to employ separate counsel in such Indemnifiable Claim at Beneficiary’s sole cost and expense. Notwithstanding the foregoing, if Beneficiary’s counsel delivers a written notice to the Company stating that such counsel has
reasonably concluded that there may be a conflict of interest between the Company and Beneficiary in the conduct of any such defense or the Company shall not, in fact, have employed counsel or otherwise actively pursued the defense of such
Indemnifiable Claim within a reasonable time, then in any such event the fees and expenses of Beneficiary’s counsel to defend such Indemnifiable Claim shall be subject to the indemnification and advancement of Expenses provisions of this Offer.

 No settlement of any Claim shall be agreed upon and entered into without the Company’s prior written consent, not to be unreasonably withheld. By
default of such Company’s prior written consent, the Company will be relieved from any and all liability for such settlement of a Indemnifiable Claim, if thereby the Beneficiary has been excluded from D&O Insurance Policy coverage or
benefit and/or if thereby the Company has been materially prejudiced. 
  

	5.	Advance on Reimbursement of Expenses 

 5.1. To the fullest extent permitted by applicable laws and
regulations and provided always that the Beneficiary has acted in good faith and within his or her capacities as a Director or Officer of the Company, the Expenses reasonably incurred by the Beneficiary in defending or investigating any
Indemnifiable Claim duly notified to the Company shall be paid by the Insurance Company or by default if any payment demand to the Insurance Company remains unsatisfied after 30 days, as well as if the maximum insurance coverage under such D&O
Policy is exceeded, by the Company, in advance of a final determination of the matter upon the request of the Beneficiary, upon presentation of satisfactory evidence that such Expenses have been incurred and remittance to the Insurance Company or,
as the case may be, the Company of Beneficiary’s written commitment to repay these Expenses in the event that it is ultimately determined that the Beneficiary is not entitled to have these Expenses reimbursed; provided that the Company shall
not be liable for that portion of such Expenses actually provided to the Beneficiary under the D&O Insurance Policy (to the fullest extent permitted by applicable laws and regulations, such undertaking shall be accepted without reference to the
financial ability of the Beneficiary to make repayment and any advances and undertakings to repay pursuant to this Section 5 shall be unsecured and interest-free); and provided further that no indemnification shall be permitted (a) in the
event that is finally determined that: (i) the Beneficiary’s conduct forming the subject matter of the Indemnifiable Claim was not consistent with the corporate 

 
interests of the Company or (ii) the Beneficiary’s conduct was in bad faith, knowingly fraudulent or deliberately dishonest or constituted willful misconduct; or (b) in respect of
Indemnifiable Claims initiated or brought by Beneficiary against the Company or its directors, officers, employees or other agents and not by way of defense, except with respect to proceedings brought to establish or enforce a right to
indemnification under this Offer or otherwise available to Beneficiary under another agreement or applicable law. 
 5.2. The termination of any Claim
pursuant to a Indemnifiable Claim by judgment, order, settlement, conviction or upon a plea of nolo contendere or its equivalent, shall not, absent specific findings in respect of Beneficiary in the judgement, conviction of the Beneficiary or an
acknowledgment by the Beneficiary in the settlement itself, create a presumption that the Beneficiary did not act in good faith and in a manner that the Beneficiary reasonably believed to be in, or not opposed to, the best interests of the Company,
and, with respect to any criminal proceeding, had reasonable cause to believe that his or her conduct was unlawful. 
 5.3. The Beneficiary shall cooperate
with the person, persons or entity making such determination with respect to the Beneficiary’s entitlement to indemnification, including providing to such person, persons or entity upon reasonable advance request any documentation or
information which is not privileged or otherwise protected from disclosure and which is reasonably available to the Beneficiary and reasonably necessary to such determination. 

5.4. If the Beneficiary is entitled under any provision of this Offer to indemnification by the Company for some or a portion of the Expenses and Losses, in
each case with respect to an Indemnifiable Claim, paid in settlement actually and reasonably incurred by or on behalf of the Beneficiary in connection with any Claim but not, however, for the total amount thereof, the Company shall nevertheless
indemnify the Beneficiary for the portion of such Expenses or Losses, in each case with respect to an Indemnifiable Claim, to which the Beneficiary is entitled. 
  

	6.	Payment by Company 

 To the fullest extent permitted by applicable laws and regulations and
provided always that the Beneficiary has acted in good faith and within his or her capacities as a Director or Officer of the Company, in the event that a Beneficiary shall not be indemnified for all the Expenses and Losses, in each case with
respect to an Indemnifiable Claim, due to (a) the failure of the Company to obtain or maintain the D&O Insurance Policy in accordance with this Offer, as well as if the maximum insurance coverage shall be exceeded or (b) the failure of
the D&O Insurance Policy to pay the Expenses or Losses, in each case with respect to an Indemnifiable Claim, the Company shall pay in full to the Beneficiary the amount of any such Expenses and Losses, in each case with respect to an
Indemnifiable Claim, to which the Beneficiary is entitled to be reimbursed or shall pay the difference between the amount received by the Beneficiary from the Insurance Company and such amount of reimbursement of the Expenses and Losses, in each
case with respect to an Indemnifiable Claim, to which it is so entitled, as the case may be. 
  

	7.	Subrogation; Primacy of Indemnification 

 Except as provided for below, in the event of payment by
the Company to Beneficiary under the Offer, the Company shall be subrogated to the extent of such payment to all of the rights of recovery of Beneficiary, who shall execute all papers required and shall do everything that may be necessary to secure
such rights, including the execution of such documents necessary to enable the Company effectively to bring suit to enforce such rights. 
 The following
paragraph applies only for the Beneficiary with a fund indemnity: 
 The Company hereby acknowledges that the Beneficiary has certain rights to
indemnification, advancement of Expenses and/or insurance provided by the Fund Indemnitors. 
 The Company hereby agrees: 

(a) that it is the indemnitor of first resort (i.e., its obligations to Beneficiary are primary and any obligation of the Fund Indemnitors to
advance expenses or to provide indemnification for the same expenses or liabilities incurred by Beneficiary are secondary); 

 (b) to the extent required by this Offer it shall advance the full amount of Expenses
incurred by Beneficiary and be liable for the full amount of all Expenses to the fullest extent permitted by applicable laws and regulations and as required by the terms of this Offer (or any other agreement between the Company and Beneficiary),
without regard to any rights Beneficiary may have against the Fund Indemnitors; and 
 (c) that it irrevocably waives, relinquishes and
releases the Fund Indemnitors from any and all Claims against the Fund Indemnitors for contribution, subrogation or any other recovery of any kind in respect thereof. 

The Company further agrees that no advancement or payment by the Fund Indemnitors on behalf of Beneficiary with respect to any Claim for which Beneficiary has
sought indemnification from the Company shall affect the foregoing and the Fund Indemnitors shall have a right of contribution and/or be subrogated to the extent of such advancement or payment to all of the rights of recovery of Beneficiary against
the Company. The Company and Beneficiary agree that the Fund Indemnitors are express third party beneficiaries of the terms hereof. 
  

	8.	Right to Payment Upon Application 

 Subject to the terms and conditions of Section 5 hereof,
all payment under the Offer, including relating to the reimbursement of the Expenses or any advances of Expenses or payment of Losses, in each case with respect to an Indemnifiable Claim, shall be paid by the Company, or on its behalf, within 30
days after a written Claim for payment has been received by the Company. Expenses reasonably incurred by the Beneficiary in connection with successfully establishing the right to payment according to the Offer, in whole or in part, shall also be
paid by the Company, to the fullest extent permitted by applicable laws and regulations. 
  

	9.	Offer Not Exclusive 

 This Offer shall not be deemed exclusive of any other rights to which the
Beneficiary may be entitled under any agreement, any vote of shareholders or disinterested directors, statute, or otherwise. 
  

	10.	Notices 

 10.1. Any notices served pursuant to this Offer shall be sent by registered mail with
return receipt requested or delivered by hand against receipt if to the Company to the registered office, if to the Beneficiary to the address indicated below at the end of this Offer. 

10.2. Any change of address shall be notified by the relevant party to the other party by registered mail with return receipt requested or delivered by hand
against receipt within fifteen (15) days of the actual date of change of address. 
 10.3. Notices shall be deemed to have been received on the date of
reception of the registered letter, as evidenced by the return receipt or, as the case may be, of the letter delivered by hand, as evidenced by the receipt. 
  

	11.	Amendments; Assignment 

 11.1. No alteration of, amendment to or waiver of any of the provisions
of this Offer shall be binding on any of the parties unless it is written and executed by a duly authorized representative of each of the parties. 
 11.2.
This Offer may not be assigned by any party hereto except with the prior written consent of the other party. Without limiting the generality or effect of the foregoing, the Beneficiary’s right to receive payments hereunder shall not be
assignable, whether by pledge, creation of a security interest or otherwise, other than by a transfer by the Beneficiary’s will or by the laws of descent and distribution, and, in the event of any attempted assignment or transfer contrary to
this Section 11.2, the Company shall have no liability to pay any amount so attempted to be assigned or transferred. 

	12.	Successors 

 The legal representatives of the parties or their successors shall be bound by and
may rely on all the terms of the Offer. The Company shall require any successor (whether direct or indirect, by purchase, merger, consolidation, reorganization or otherwise) to all or substantially all of the business or assets of the Company, by
agreement in form and substance satisfactory to the Beneficiary and his or her counsel, expressly to assume and agree to perform this Offer in the same manner and to the same extent the Company would be required to perform if no such succession had
taken place. This Offer shall be binding upon and inure to the benefit of the Company and any successor to the Company, including without limitation any person acquiring directly or indirectly all or substantially all of the business or assets of
the Company whether by purchase, merger, consolidation, reorganization or otherwise (and such successor will thereafter be deemed the “Company” for purposes of this Offer), but shall not otherwise be assignable or delegatable
by the Company. This Offer shall inure to the benefit of and be enforceable by the Beneficiary’s personal or legal representatives, executors, administrators, heirs, distributees, legatees and other successors. 

 

	13.	Miscellaneous Provisions 

 13.1. This Offer shall continue until and terminate upon the later of
(a) ten years after the date that the Beneficiary shall have ceased to serve as a Director or Officer of the Company or a Subsidiary or, at the request of the Company, as a director, officer, partner, trustee, member, employee or agent of
another corporation, partnership, joint venture, trust, limited liability company or other enterprise or (b) the final termination of all Claims pending on the date set forth in clause (a) in respect of which the Beneficiary is granted
rights of indemnification or advancement of Expenses hereunder and of any Claim commenced by the Beneficiary pursuant to Section 8 of this Offer relating thereto. 

13.2. The parties agree that the provisions contained in the preamble and Exhibit hereto form an integral part of the Offer. 

13.3. Should any of the provisions of this Offer be held null and void or unenforceable for any reason whatsoever, the parties undertake to use their best
efforts to remedy the causes of such nullity, so that, except where such is impossible, the Offer shall remain in force without any discontinuity. 
 13.4.
The parties agree to provide any information as well as to execute and to deliver all documents reasonably required for the performance of this Offer. 
  

	14.	Applicable Law 

 This Offer shall be governed as to its validity, construction and performance in
accordance with the laws of the Republic of France. 
  

	15.	Disputes  

 Any dispute arising from the Offer or which are a result or a consequence thereof
shall be made subject to the jurisdiction of the Tribunal de Commerce de Paris. 

	
	 Executed in                     

On                 

In two (2) original copies

	
	   

	 By

CEO (Directeur Général)

  

			
		
	Accepted by	 	 
	Residing at	 	 
	On	 	 

 being a Director or an Officer of the Company, as these terms are defined in the Offer 

who hereby declares that he or she: 
  

	 	•	 	has a good and fair knowledge of the terms, conditions and exclusions of the Offer; 

  

	 	•	 	• is fully aware that applicable French laws and regulations limit a company’s ability to indemnify its directors against liability; 

 

	 	•	 	is fully aware that U.S. securities laws may also limit a company’s ability to indemnify in respect of liabilities arising under U.S. securities laws; and 

 

	 	•	 	formally and irrevocably accepts the Offer, as it stands.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00275-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00275-of-00352.parquet"}]]